ConductScience.org, home

Paper39625587

CAR T-cell therapy to treat multiple myeloma: current state and future directions.

Reddy ST and 2 others. Cancer Metastasis Rev, 2024. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. CAR T-cell therapy to treat multiple myeloma: current state and future directions. Papers, record 39625587. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39625587

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CAR T-cell therapy to treat multiple myeloma: current state and future directions.
PubMed
Journal
Cancer Metastasis Rev
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.93, provisional
iCite
Revised in PubMed
2026-07-15
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Reddy STSiddhartha Thammineni
2Hosoya HHitomi
3Mikkilineni LLekha

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
Immunotherapy, AdoptiveMajor topic
Receptors, Chimeric AntigenMajor topic
Humans
Animals
T-Lymphocytes

References106

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137592106Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.Nat Med2023https://conductscience.org/library/papers/37592106PubMed
231042825Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.N Engl J Med2019https://conductscience.org/library/papers/31042825PubMed
333626253Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.N Engl J Med2021https://conductscience.org/library/papers/33626253PubMed
436623248Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.J Clin Oncol2023https://conductscience.org/library/papers/36623248PubMed
537558706Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.Blood Cancer J2023https://conductscience.org/library/papers/37558706PubMed
634175021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet2021https://conductscience.org/library/papers/34175021PubMed
735658469Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.J Clin Oncol2023https://conductscience.org/library/papers/35658469PubMed
837272512Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.N Engl J Med2023https://conductscience.org/library/papers/37272512PubMed
936762851Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.N Engl J Med2023https://conductscience.org/library/papers/36762851PubMed
1028726797Multiple myeloma.Nat Rev Dis Primers2017https://conductscience.org/library/papers/28726797PubMed
1127511158International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.Lancet Oncol2016https://conductscience.org/library/papers/27511158PubMed
1226763514Multiple Myeloma: Diagnosis and Treatment.Mayo Clin Proc2016https://conductscience.org/library/papers/26763514PubMed
1333602913Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.Blood Cancer J2021https://conductscience.org/library/papers/33602913PubMed
1428187291The Principles of Engineering Immune Cells to Treat Cancer.Cell2017https://conductscience.org/library/papers/28187291PubMed
1531848460Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nat Rev Clin Oncol2020https://conductscience.org/library/papers/31848460PubMed
1628541315Therapeutic T cell engineering.Nature2017https://conductscience.org/library/papers/28541315PubMed
1726169254Engineering CAR-T cells: Design concepts.Trends Immunol2015https://conductscience.org/library/papers/26169254PubMed
1833824268CAR-T cell therapy: current limitations and potential strategies.Blood Cancer J2021https://conductscience.org/library/papers/33824268PubMed
1927412889T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.Blood2016https://conductscience.org/library/papers/27412889PubMed
2038307865GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.Blood Cancer J2024https://conductscience.org/library/papers/38307865PubMed

See all 106 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42375393Development of chimeric antigen receptors targeting the γδ T cell receptor.Mol Ther Oncol2026https://conductscience.org/library/papers/42375393PubMed
42137138Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis.Front Oncol2026https://conductscience.org/library/papers/42137138PubMed
41702648Corticosteroids ameliorate CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment.J Immunother Cancer2026https://conductscience.org/library/papers/41702648PubMed
41654863Ubiquitin-centered post-translational modification crosstalk orchestrates tumor immunity and immunotherapy response.Exp Hematol Oncol2026https://conductscience.org/library/papers/41654863PubMed
41488642CAR-γδ T cells: a new paradigm of programmable innate immune sentinels and their systemic applications in cancer and beyond.Front Immunol2025https://conductscience.org/library/papers/41488642PubMed
414286222025 Update of Cellular Immunotherapy for Plasma Cell Disorders.Turk J Haematol2026https://conductscience.org/library/papers/41428622PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GPRC5D55507PubTator's text mininghttps://conductscience.org/library/genes/55507NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39625587

GET https://conductscience.org/api/papers/v1/39625587/references?page=2